By
Donald Zuhn --
In
contrast with the first quarter of 2010, when the Life Sciences sector
(biotechnology and medical devices) led all sectors with $1.3 billion invested
in 160 deals, but still suffered through a 26% drop in dollars and a 21%
decrease in deals as compared with the fourth quarter of 2009, the news was all
good for the industry in the second quarter. Thus, not only did the Life Sciences sector experience
increases of 52% in dollars and 36% in deals ($2.1 billion invested in 234
deals), but the sector ran its string of consecutive quarters as
the top sector in terms of dollars invested to five. Interestingly, the biotech industry
received as much funding in the second quarter ($1.3 billion going into 139
deals) as the Life Sciences sector received as a whole in the first
quarter. The biotech numbers constituted a 59%
increase in dollars and 34% in deal volume as compared with the first quarter.
Of
the seventeen sectors analyzed for the report, the NVCA noted that
eleven experienced
dollar increases in the second quarter, including the Life Sciences,
Computers
and Peripherals (48% increase), Consumer Products and Services (44%),
and IT
Services (28%) sectors.
In
a press release issued by the NVCA and PricewaterhouseCoopers, Tracy Lefteroff,
global managing partner of the venture capital practice at
PricewaterhouseCoopers, noted that the first quarter numbers had venture
capitalists feeling more positive about the economic outlook for
investment. She also noted that
quarterly investment had topped the $6 billion mark for the first time since
the third quarter of 2008.
According to Ms. Lefteroff, the likely driver for the strong rebound in
investment was the rise in Life Sciences companies looking to go public in the second
quarter. She added that "[i]f
the markets remain positive, we'll likely continue to see robust investment
levels for the remainder of the year, with VC funding in 2010 poised to surpass
2009 levels."
Comments